Gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. While the global pipeline for adeno-associated virus (AAV) gene therapy continues to expand, there are key challenges, such as characterization data to better understand AAV, that still need to be addressed. One of the fundamental characterization datasets that should be assessed, especially in a high-throughput format, is AAV capsid concentration in solution.

- Antibody Discovery & Screening
- Antibody neutralization assays
- Host Immune Response: immune-based assays for T cell activation, exhaustion, NK and T cell mediated cell killing
- Functional antibody screens: phagocytosis, antibody-dependent internalization
- Vaccine development: epitope screening
- Target Identification with cell-based target screening, display-based library screens, phage, yeast and VLP
- Antibody titers and cell health

- Differences between aseptic and non-aseptic connection and disconnection
- Why connection and disconnection technologies influence your process integrity
- Why validation is key for process safety

- Learn the challenges of large-scale bioprocess filtration.
- Explore how filtration processes have evolved.
- Understand how Annex 1 and CCS influence filtration processes.

- Discover the benefits of using all-in-one, chemically-defined cryopreservation solutions.
- Understand when cold storage may be a suitable alternative to cryopreservation.
- Learn how custom solutions with recombinant human albumin support post-thaw viability.

- See how we help customers implement SU systems into their commercial manufacturing processes.
- Learn how capacity expansions are improving lead times on a global and regional scale.
- Get an inside look at the latest innovations that are driving a more robust supply chain